Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.91 USD | -1.51% | -2.15% | -12.84% |
05-14 | Stephens Initiates Exelixis With Equalweight Rating, $23 Price Target | MT |
05-10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.84% | 6.09B | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.
- Exelixis Says Enrollment Complete For Phase 3 Trial For Cabozantinib in Combination With Atezolizumab